# A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease

> **NCT03765762** · PHASE2 · COMPLETED · sponsor: **Alkahest, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Severe Alzheimer Disease

## Interventions

- **DRUG:** GRF6019
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03765762
- **Lead sponsor:** Alkahest, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-15
- **Primary completion:** 2019-12-17
- **Final completion:** 2019-12-17
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03765762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03765762, "A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03765762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*